BDX Becton Dickinson Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
00:04
Jun 04
Jim Cramer Host, Mad Money CNBC
BDX at historically low valuation.
Becton Dickinson is at its lowest valuation relative to the market in history, making it a bargain. Buy now.
BDX
HIGH
23:44
May 07
Jim Cramer Host, Mad Money CNBC
BD strong quarter, AI healthcare growth.
Becton Dickinson reported a strong quarter with a top and bottom line beat, raised full-year earnings guidance, and has a portfolio that is 90% recurring revenue. The company is benefiting from AI in healthcare (patient monitoring), GLP-1 injectables, tissue regeneration, and home care solutions, making it a compelling investment.
BDX 1ST
HIGH
22:45
Apr 11
Matthew McLennan Co-Head of Investment Management, Goldman Sachs We Study Billionaires
BDX is a scarce asset with margin of safety.
Becton Dickinson (BDX) is a world leader in syringes and catheters with over 50% market share, giving it scale economies, embeddedness in hospital systems, and a regenerative feedback loop for innovation. It trades at 12-13 times earnings (8% earnings yield), implying the market expects little growth, yet the company is focused, generates strong free cash flow, and uses it for dividends and buybacks. It is well-positioned to benefit from the growth of biologics and integration of technology like AI.
BDX 1ST
HIGH

About BDX Analyst Coverage

Buzzberg tracks BDX (Becton Dickinson) across 2 sources. 3 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (100%). 3 total trade ideas tracked.